Cognition Therapeutics, Inc. - Common Stock (CGTX)

Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMD

Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 Months Experienced Slower Lesion Growth than Participants Receiving Placebo

PITTSBURGH, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ensure that the patients selected are most likely to benefit from treatment.

- Chemical process enhances room temperature stability -

Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference

– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –

Cognition Therapeutics Is Targeting A Critical Form Of Dementia

PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025.

Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial

Cognition Therapeutics' CT1812 improves dementia with Lewy bodies outcomes, reducing anxiety, hallucinations, and functional decline in trials.

- Improvements Across Measures of Behavior, Function, Cognition and Movement -

– Topline results in second dementia indication expected to be reported in December 2024 –

- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

- CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company’s presentation will focus primarily on the results from the successful Phase 2 ‘SHINE’ study of CT1812 in mild-to-moderate Alzheimer’s disease. In addition, Ms. Ricciardi will provide an overview of the Company’s ongoing clinical programs, including the Phase 2 ‘SHIMMER’ study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER’ study are expected by year-end 2024.

Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.

- Patient characteristics are consistent with other DLB studies -

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology - 

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’

PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness Month, is titled “Executing Clinical Research in Dementia with Lewy Bodies (DLB).”

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.

Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024